Newer cases are also starting to be treated by taxotere and gemcitabine.
Taxotere is similar to Oncovin used in CHOP; it irreversibly binds beta tubulin halting formation of microtubules.
Taxotere has an added benefit though; it also phosphorylates bcl-2 to halt the anti-apoptotic pathway.
The dual effect of taxotere on integral cancer pathways makes it a more potent drug than Oncovin.
Gemcitabene is a nucleoside analog and when incorporated into DNA during replication leads to apoptosis; the fluorine on the 2’ carbon atom stops other nucleosides from attaching.
The most important part of this combination therapy, however, is the synergism between the drugs.
While researchers are not entirely sure of the mechanism, there is evidence of synergistic effects of taxotere and gemcitabine when used in combination.
This allows for decreased dosages of each single agent with an increased apoptotic response.
Newer cases are also starting to be treated by taxotere and gemcitabine. Taxotere is similar to Oncovin used in CHOP; it irreversibly binds beta tubulin halting formation of microtubules. Taxotere has an added benefit though; it also phosphorylates bcl-2 to halt the anti-apoptotic pathway. The dual effect of taxotere on integral cancer pathways makes it a more potent drug than Oncovin. Gemcitabene is a nucleoside analog and when incorporated into DNA during replication leads to apoptosis; the fluorine on the 2’ carbon atom stops other nucleosides from attaching. The most important part of this combination therapy, however, is the synergism between the drugs. While researchers are not entirely sure of the mechanism, there is evidence of synergistic effects of taxotere and gemcitabine when used in combination. This allows for decreased dosages of each single agent with an increased apoptotic response.
Follicular dendritic cell sarcoma